Translational Research In Oncology Us Inc
Translational Research In Oncology Us Inc consistently directs 100% of reported officer compensation to programs, maintaining strong asset growth.
EIN: 200132719 · Los Angeles, CA · NTEE: H30 · Updated: 2026-03-28
Is Translational Research In Oncology Us Inc Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Translational Research In Oncology Us Inc directs 100% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Translational Research In Oncology Us Inc
Translational Research In Oncology Us Inc (EIN: 200132719) is a nonprofit organization based in Los Angeles, CA, classified under NTEE code H30. The organization reported total revenue of $15.7M and total assets of $25.8M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Translational Research In Oncology Us Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Translational Research In Oncology Us Inc is a large nonprofit that has been operating for 21 years, with 11 years of IRS 990 filings on record (2010–2023). Revenue has grown at a compound annual rate of 3.4%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $8.4M |
| Total Expenses | $8.5M |
| Surplus / Deficit | $-82,599 |
| Total Assets | $24.6M |
| Total Liabilities | $9.2M |
| Net Assets | $15.3M |
| Operating Margin | -1.0% |
| Debt-to-Asset Ratio | 37.6% |
| Months of Reserves | 34.6 months |
Financial Health Grade: B
In 2023, Translational Research In Oncology Us Inc reported a deficit of $83K with expenses exceeding revenue, holds 34.6 months of operating reserves (strong position), has a debt-to-asset ratio of 37.6% (moderate leverage).
Financial Trends
Over 11 years of filings (2010–2023), Translational Research In Oncology Us Inc's revenue has grown at a compound annual growth rate (CAGR) of 3.4%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -11.9% | +24.5% | +7.7% |
| 2022 | +15.8% | -10.9% | -3.1% |
| 2021 | +9.0% | +11.7% | +7.2% |
| 2020 | +11.3% | +14.5% | +5.0% |
| 2019 | -6.5% | -4.6% | +47.1% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 8200 |
| IRS Ruling Date | 2005 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Translational Research In Oncology Us Inc with a Mission Score of 95 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 0%
- programs: 100%
- fundraising: 0%
According to IRS 990 filings, Translational Research In Oncology Us Inc allocates its expenses as follows: admin: 0%, programs: 100%, fundraising: 0%. With 100% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $83K, with expenses exceeding revenue.
- Debt-to-asset ratio: 37.6%.
Executive Compensation Analysis
Translational Research In Oncology Us Inc consistently reports 0% officer compensation across all available filings, which is highly unusual for an organization of its size with revenues exceeding $8 million in recent years. This suggests that executive leadership may be entirely volunteer-based or compensated through an affiliated entity, warranting further inquiry for full financial transparency.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Translational Research In Oncology Us Inc's IRS 990 filings:
- Consistent 0% officer compensation for an organization of this size, which may obscure actual leadership compensation if paid by an affiliate.
Strengths
The following positive indicators were identified for Translational Research In Oncology Us Inc:
- Strong and consistent asset growth, from $7.8 million in 2011 to $24.5 million in 2023.
- High apparent program efficiency due to reported 0% officer compensation, suggesting funds are directed to mission.
- Stable financial operations with consistent revenue generation over more than a decade.
Frequently Asked Questions about Translational Research In Oncology Us Inc
Is Translational Research In Oncology Us Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, Translational Research In Oncology Us Inc (EIN: 200132719) some concerns. Mission Score: 95/100. 1 red flag identified, 3 strengths noted.
How does Translational Research In Oncology Us Inc spend its money?
Translational Research In Oncology Us Inc directs 100% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Translational Research In Oncology Us Inc tax-deductible?
Translational Research In Oncology Us Inc is registered as a tax-exempt nonprofit (EIN: 200132719). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How does Translational Research In Oncology Us Inc manage to report 0% officer compensation with its revenue and asset size?
The consistent reporting of 0% officer compensation across all filings suggests that executive leadership may be entirely volunteer-based or compensated through an affiliated entity. This practice, while potentially indicating high efficiency, requires further investigation to understand the full compensation structure and ensure complete transparency.
What is the primary source of revenue for Translational Research In Oncology Us Inc?
While the provided data shows total revenue, it does not specify the breakdown of revenue sources (e.g., grants, contributions, program service revenue). A deeper dive into their 990 forms would be needed to identify the primary sources.
Has Translational Research In Oncology Us Inc experienced significant financial fluctuations?
The organization has shown consistent growth in assets and generally stable revenue streams, with some year-to-year variations in revenue and expenses. For example, revenue in 2023 was $8,434,391, down from $9,572,095 in 2022, but overall, the trend is upward over the long term.
Filing History
IRS 990 filing history for Translational Research In Oncology Us Inc showing financial trends over 11 years of public records:
Over 11 years of IRS 990 filings (2010–2023), Translational Research In Oncology Us Inc's revenue has grown by 53.6%, moving from $5.5M to $8.4M. Total assets increased by 195.7% over the same period, from $8.3M to $24.6M. Total functional expenses rose by 55.4%, from $5.5M to $8.5M. In its most recent filing year (2023), Translational Research In Oncology Us Inc reported a deficit of $83K, with expenses exceeding revenue. The organization holds $9.2M in liabilities against $24.6M in assets (debt-to-asset ratio: 37.6%), resulting in net assets of $15.3M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $8.4M | $8.5M | $24.6M | $9.2M | — | — |
| 2022 | $9.6M | $6.8M | $22.8M | $9.0M | — | — |
| 2021 | $8.3M | $7.7M | $23.5M | $10.9M | — | View 990 |
| 2020 | $7.6M | $6.9M | $22.0M | $9.8M | — | View 990 |
| 2019 | $6.8M | $6.0M | $20.9M | $9.4M | — | View 990 |
| 2015 | $7.3M | $6.3M | $14.2M | $9.8M | — | View 990 |
| 2014 | $7.5M | $6.2M | $13.8M | $10.3M | — | View 990 |
| 2013 | $4.9M | $4.8M | $10.5M | $8.2M | — | View 990 |
| 2012 | $5.6M | $5.4M | $8.8M | $6.6M | — | View 990 |
| 2011 | $4.4M | $4.6M | $7.8M | $5.8M | — | View 990 |
| 2010 | $5.5M | $5.5M | $8.3M | $7.1M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $8.4M, expenses of $8.5M, and assets of $24.6M (revenue -11.9% year-over-year).
- 2022: Revenue of $9.6M, expenses of $6.8M, and assets of $22.8M (revenue +15.8% year-over-year).
- 2021: Revenue of $8.3M, expenses of $7.7M, and assets of $23.5M (revenue +9.0% year-over-year).
- 2020: Revenue of $7.6M, expenses of $6.9M, and assets of $22.0M (revenue +11.3% year-over-year).
- 2019: Revenue of $6.8M, expenses of $6.0M, and assets of $20.9M (revenue -6.5% year-over-year).
- 2015: Revenue of $7.3M, expenses of $6.3M, and assets of $14.2M (revenue -2.5% year-over-year).
- 2014: Revenue of $7.5M, expenses of $6.2M, and assets of $13.8M (revenue +52.3% year-over-year).
- 2013: Revenue of $4.9M, expenses of $4.8M, and assets of $10.5M (revenue -12.5% year-over-year).
- 2012: Revenue of $5.6M, expenses of $5.4M, and assets of $8.8M (revenue +28.1% year-over-year).
- 2011: Revenue of $4.4M, expenses of $4.6M, and assets of $7.8M (revenue -20.3% year-over-year).
- 2010: Revenue of $5.5M, expenses of $5.5M, and assets of $8.3M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Translational Research In Oncology Us Inc:
Data Sources and Methodology
This transparency report for Translational Research In Oncology Us Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.